Rigel Pharmaceuticals (RIGL) Total Debt (2019 - 2026)

Rigel Pharmaceuticals has reported Total Debt for 8 years, with the latest figure at $74.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 25.06% year-over-year to $74.7 million; the trailing twelve-month figure through Mar 2026 stood at $74.7 million (up 25.06% YoY), and the FY2025 full-year result was $52.3 million, down 12.38% from the prior year.
• Total Debt for Q1 2026 stood at $74.7 million, up from $52.3 million in the prior quarter.
• The five-year high for Total Debt was $74.7 million in Q1 2026, with the low at $29.8 million in Q2 2022.
• Average Total Debt over 5 years is $54.2 million, with a median of $59.7 million recorded in 2023.
• Year-over-year, Total Debt soared 99.68% in 2023 and retreated 12.38% in 2025.
• Tracing RIGL's Total Debt over 5 years: stood at $39.4 million in 2022, then surged by 51.09% to $59.6 million in 2023, then rose by 0.13% to $59.7 million in 2024, then fell by 12.38% to $52.3 million in 2025, then soared by 42.89% to $74.7 million in 2026.
• The last three Total Debt figures came in at $74.7 million (Q1 2026), $52.3 million (Q4 2025), and $59.7 million (Q3 2025), per Business Quant data.

Peer Comparison